Literature DB >> 11605936

Role of potassium channels in isoflurane- and sevoflurane-induced attenuation of hypoxic pulmonary vasoconstriction in isolated perfused rabbit lungs.

R Liu1, M Ueda, N Okazaki, Y Ishibe.   

Abstract

BACKGROUND: Although potassium channels are thought to be responsible for the initiation of hypoxic pulmonary vasoconstriction (HPV), their role in the HPV-inhibitory effect of volatile anesthetics is unclear. The current study tested if the HPV-inhibitory effect of isoflurane and sevoflurane can be affected by changing the potassium-channel opening status with specific potassium-channel inhibitors in isolated rabbit lungs.
METHODS: Isolated rabbit lungs were divided into eight groups (n = 6 each in isoflurane groups and n = 8 in sevoflurane groups): those receiving no inhibitor treatment = control-isoflurane and control-sevoflurane groups; those treated with an adenosine triphosphate-sensitive potassium (K(ATP))-channel inhibitor, glibenclamide = glibenclamide-isoflurane and glibenclamide-sevoflurane groups; those treated with a high-conductance calcium-activated potassium (K(Ca))-channel inhibitor, iberiotoxin = iberiotoxin-isoflurane and iberiotoxin-sevoflurane groups; and those treated with a voltage-sensitive potassium (Kv)-channel inhibitor, 4-aminopyridine = 4-aminopyridine-isoflurane and 4-aminopyridine-sevoflurane groups. The effect of anesthetic on HPV was tested by exposure of the lungs to isoflurane at a concentration of 0, 0.5, 1, or 2 minimum alveolar concentration, or to sevoflurane at a concentration of 0, 0.5, 1, or 1.62 minimum alveolar concentration. The relation between anesthetic concentrations and the HPV response was analyzed by the Wagner equation.
RESULTS: The inhibition of Kv channels by 4-aminopyridine and K(Ca) channels by iberiotoxin augmented the HPV response. The isoflurane-induced attenuation of HPV was attenuated by voltage-sensitive potassium-channel inhibition with 4-aminopyridine, potentiated by K(Ca)-channel inhibition with iberiotoxin, but not affected by K(ATP)-channel inhibition with glibenclamide. The sevoflurane-induced attenuation of HPV was not affected by any of the potassium-channel inhibitors.
CONCLUSIONS: Isoflurane may modulate the HPV response partially through K(Ca) and Kv channels, but sevoflurane may attenuate the HPV response through other pathways rather than through the currently investigated potassium channels in isolated rabbit lungs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605936     DOI: 10.1097/00000542-200110000-00024

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  5 in total

Review 1.  [Management of patients with pulmonary hypertension].

Authors:  B Preckel; S Eberl; J Fräßdorf; M W Hollmann
Journal:  Anaesthesist       Date:  2012-07       Impact factor: 1.041

2.  Marathoners' Breathing Pattern Protects Against Lung Injury by Mechanical Ventilation: An Ex Vivo Study Using Rabbit Lungs.

Authors:  Yoshiaki Oshima; Naoto Okazaki; Kazumi Funaki; Akihiro Otsuki; Shunsaku Takahashi; Tomomi Harada; Yoshimi Inagaki
Journal:  Yonago Acta Med       Date:  2020-10-05       Impact factor: 1.641

3.  Reversible cause of intra operative hypoxia in an aspirated patient.

Authors:  Amar Nandhakumar; Suresh Jayabalan; Nandhakumar Subramaniyan
Journal:  Indian J Anaesth       Date:  2015-06

4.  Isoflurane pre-treatment before cardiopulmonary bypass alleviates neutrophil accumulation in dog lungs.

Authors:  Gui-Zhi Du; Hong Gao; Jin Liu; Guan-Sheng Wu; Xiang He; Xiang-Gang Zeng; Xaun-Yi Hu; Xin-Hua Li
Journal:  Cardiovasc J Afr       Date:  2010-11-09       Impact factor: 1.167

5.  Role of Ryanodine Type 2 Receptors in Elementary Ca2+ Signaling in Arteries and Vascular Adaptive Responses.

Authors:  Mario Kaßmann; István András Szijártó; Concha F García-Prieto; Gang Fan; Johanna Schleifenbaum; Yoland-Marie Anistan; Christoph Tabeling; Yu Shi; Ferdinand le Noble; Martin Witzenrath; Yu Huang; Lajos Markó; Mark T Nelson; Maik Gollasch
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.